Ovid Therapeutics Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Ovid Therapeutics Inc. (OVID) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $5.00 million as of 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2019-03-07
- 2018-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $5.00M.
- 2018-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $22.00M.
- 2018-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $40.10M.
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $45.00M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2018-12-31 | $5.00M 10-K · filed 2019-03-07 |
| 2018-09-30 | $22.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $40.10M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $45.00M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |